Skip to content
Golgi news
7 November 2024
The Michael J. Fox Foundation Launches Target De-Risking Initiative for Parkinson’s Disease
Read more
29 August 2023
Golgi Neurosciences partners with CDD Vault to Drive Innovation in Neurodegenerative Disease Treatment
Read more
25 July 2023
Golgi Neurosciences and Breye Therapeutics announce successful closing of P2X7 receptor antagonist program transfer
Read more
5 July 2023
Golgi Neurosciences, a unique incubator to combat neurodegenerative disorders, starts operating
Read more
portfolio company news
28 February 2025
Alcatraz Therapeutics being awarded “New Company with more transformative potential” at Bio-Neurosciences 2025
Read more
20 December 2024
Libra Therapeutics Advances LBR-2950 Program securing a $5 Million MJFF grant.
Read more
10 December 2024
Muna Therapeutics Announces Strategic Alliance with GSK to Advance Alzheimer’s Research
Read more
26 July 2024
Lario Therapeutics Secures $6 Million MJFF Grant for Groundbreaking Parkinson’s Research
Read more
17 February 2024
Acousia Therapeutics Launches PROHEAR-Study with First Patient Enrolled
Read more
26 January 2024
Breye Therapeutics to start Phase 1b/2a clinical trials
Read more
9 November 2023
Lario Therapeutics being awarded “Company Making a Difference 2023 Preclinical” by the Loulou Foundation
Read more
10 October 2023
Acousia Therapeutics receiving the approval for Phase 2 clinical trials
Read more
This website or its third party tools use cookies, which are necessary to its functioning and required for the purposes illustrated in the cookie policy. If you want to know more or withdraw your consent to all or some of the cookies, please refer to the cookie policy . Accept Privacy policy 
